|
RS
|
|
Mean, median (range)
|
12, 12 (0–17)
|
11, 12 (0–17)
|
|
RS 0–10; n (%)
|
500 (36.2%)
|
5 (38.5%)
|
|
RS 11–17; n (%)
|
883 (63.8%)
|
8 (61.5%)
|
|
Age at diagnosis
|
|
Mean, median (range); years
|
57, 57 (22–90)
|
55, 54 (35–79)
|
|
< 40 years; n (%)
|
61 (4.4%)
|
2 (15.4%)
|
|
40–49 years; n (%)
|
328 (23.7%)
|
3 (23.1%)
|
|
≥ 50 years; n (%)
|
994 (71.9%)
|
8 (61.5%)
|
|
Tumor size, median (range); cm
|
1.31, 1.2 (0.3–5.8)
|
1.5, 1.3 (0.5–3.5)
|
|
Multifocality; n (%)
|
291 (21%)
|
6 (46.2%)
|
|
LVI; n (%)
|
262 (18.9%)
|
4 (30.8%)
|
|
Local treatment; n (%)
|
|
BCS only
|
46 (3.3%)
|
2 (15.4%)
|
|
BCS and radiation therapy
|
923 (66.7%)
|
7 (53.8%)
|
|
Total mastectomy
|
410 (29.6%)
|
4 (30.8%)
|
|
Total mastectomy and radiation therapyb
|
4 (0.3%)b
|
0
|
|
Systemic therapy; n (%)
|
|
Endocrine therapy only
|
1176 (85%)
|
8 (61.5%)
|
|
Endocrine therapy and chemotherapya
|
165 (11.9%)a
|
4 (30.8%)
|
|
No systemic therapy
|
42 (3%)
|
1 (7.7%)
|
|
Median follow-up (range); months
|
51.9 (0.9–108.3)
|
71.4 (43.2–86.8)
|
|
Time to LRR, median (range), months
|
–
|
36.5 (9.7–74.3)
|
